PALACE: Cemiplimab Trial According to ctDNA Levels

This is an open-label, non-randomised, phase II, multicenter clinical trial. 63 stage IV or stage IIIB/C not candidates for definitive chemo/radiotherapy or surgical resection non-small cell lung cancer (NSCLC) per the 8th edition TNM with no prior systemic anti-cancer therapy will be enrolled in this trial to determine whether therapy decision making based on ctDNA analysis improves overall survival.

Trial Details

NCT ID
NCT06917573
Phase
PHASE2
Sponsor
Fundación GECP
Status
RECRUITING
Cancer Type
Lung Cancer
Interventions
  • Cemiplimab
  • Carboplatin
  • Paclitaxel
Locations (sample)
  • Alicante, Alicante, Spain|38.34517,-0.48149
  • Elche, Alicante, Spain|38.26218,-0.70107
  • Badalona, Barcelona, Spain|41.45004,2.24741
  • Barcelona, Barcelona, Spain|41.38879,2.15899
  • Barcelona, Barcelona, Spain|41.38879,2.15899

Key Eligibility Criteria

  • Histologically confirmed stage IV or stage IIIB/C not candidates for definitive chemo/radiotherapy or surgical resection non-small cell lung cancer…
  • ECOG performance status 0-1
  • Patients aged ≥ 18 years
  • Prior adjuvant or neoadjuvant chemotherapy for early stage is permitted if completed at least 6 months prior to enrolment

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Lung Cancer Trials on Trialify →